Hemato oncology testing market seen reaching $7.76 billion by 2030

The hemato oncology testing market is projected to grow from $3.93 billion in 2025 to $7.76 billion by 2030, driven by precision oncology diagnostics, genomic testing investment and AI-powered tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Hemato oncology testing is used to detect blood cancers and other blood disorders early, which can improve treatment decisions and patient outcomes. - The market’s projected growth points to rising demand for advanced diagnostics across hospitals, labs and oncology care settings. - Increased testing capacity also reflects broader adoption of molecular diagnostics, sequencing and data-driven cancer care.

What happened: - The Business Research Company projected the global hemato oncology testing market will rise from $3.93 billion in 2025 to $4.5 billion in 2026. - The firm forecast the market will reach $7.76 billion by 2030. - The report put the market’s 2025-2026 CAGR at 14.4% and the 2026-2030 CAGR at 14.6%. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample report is available here. - The full report is available here.

The details: - Hemato oncology testing includes diagnostic procedures for blood disorders and blood cancers. - The testing is used to identify anemia, infections, hemophilia, blood clotting abnormalities and types of leukemia. - Historical growth has been supported by more blood cancer cases, more hospital diagnostic labs, greater awareness of early cancer screening, more clinical research and wider availability of advanced testing reagents. - Forecast growth is linked to greater use of precision oncology diagnostics, more genomic testing infrastructure investment, growth in AI-powered diagnostic platforms, stronger demand for companion diagnostics and ongoing assay innovation. - Key market trends include wider use of molecular diagnostic testing, more next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, more automated laboratory testing and deeper use of data analytics in hemato-oncology. - The report described rising hematologic cancer prevalence as a major growth driver. - The report cited Cancer Research UK data showing leukemia incidence in the UK at about 17.9 cases per 100,000 people annually from 2024 to 2026, with a projected decline to about 17.4 cases per 100,000 by 2038 to 2040.

Between the lines: - The forecast suggests cancer diagnostics is moving toward more specialized, higher-complexity testing rather than basic screening alone. - Investment in genomic infrastructure and AI tools signals a market shaped by speed, accuracy and personalized treatment selection. - Regional growth patterns suggest mature markets still dominate revenue, while emerging markets are expanding capacity faster.

What's next: - The report expects continued adoption of molecular diagnostics, sequencing and automation across hemato oncology testing. - Demand should also rise as companion diagnostics become more central to treatment planning. - The Business Research Company said its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The company also provided contact details for its expert team and listed its website and social media channels, including LinkedIn, Facebook and X.